See relapses that others miss.
Foresight’s peer-reviewed and proprietary minimal residual disease (MRD) technology has been validated in hundreds of real-world samples from patients with B-cell malignancies, lung cancer, and breast cancer. At the end of therapy Foresight detected circulating tumor DNA in all the patients who would relapse.
Existing methods missed most of them.View Publications
See levels below 1 part per million
By tracking unique genomic differences between cancer and healthy cells with unparalleled accuracy, Foresight can detect ctDNA levels below 1 part per million, which is up to 100 times lower than other methods.